WeightControl.com: How does Tripeptide differ from semaglutide?
Response: Tirzepatide is a once weekly GIP and GLP-1 receptor agonist while semaglutide was a once weekly GLP-1 receptor agonist
WeightControl.com: What should readers take away from your report?
Response: The readers should take away that tirzepatide is effective in all subjects with obesity independently of the duration of their history of obesity.
WeightControl.com: What recommendations do you have for future research as a result of this work?
Response: Long term data are needed in order to investigate if the short term surprising results are also maintained on long term.
Citation: ECO 2024 abstract:
Tirzepatide reduced body weight and waist circumference in people with overweight or obesity regardless of disease duration: post hoc analysis of the SURMOUNT 1-4 trials
https://eco2024.org/assets/docs/draft-programme.pdf?a=7890
The information on WeightControl.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.
Last Updated on March 17, 2024 by weightcontrol